Lewis Hamilton produced a clinical and dominant display to win the Belgian Grand Prix at Spa

“I think it is an opportunity for nurses to learn a skillset you don’t learn in nursing school.” – Jeffin Bush

Top Breast Cancer Surgeons Discuss Advanced Surgical Options

“I think it is an opportunity for nurses to learn a skillset you don’t learn in nursing school.” – Jeffin Bush

China has approved its third coronavirus vaccine for the second phase of clinical trials as it reported 12 new COVID-19 cases, taking the total number of infections in the country to 82,816. China has approved three coronavirus vaccines, including the one developed by Chinese military, the People's Liberation Army (PLA) for clinical trials. An "inactivated" vaccine developed by Wuhan Institute of Biological Products under the China National Pharmaceutical Group (Sinopharm) and the Wuhan Institute of Virology (WIV) started its clinical trials, state-run Xinhua news agency reported.

An "inactivated" vaccine consists of virus particles, bacteria, or other pathogens that have been grown in culture and then lose disease producing capacity. In contrast, live vaccines use pathogens that are still alive. WIV has been in the eye of the storm in recent weeks as US President Donald Trump and top American officials alleged that the coronavirus may have escaped from there and demanded a probe into it. An official of the WIV denied it, terming the allegation "entirely based on speculation".

A total of 96 persons in three age groups have received the vaccine in the first phase of clinical trial as of April 23. The vaccine has shown good safety results so far and vaccine receivers are still under observation, said the Chinese pharmaceutical company Sinopharm. The randomised, double-blind and placebo-controlled clinical trials of the inactivated vaccine are conducted in Jiaozuo, central China's Henan Province, and the second phase of clinical trial will focus on the vaccination procedure, it said.

The vaccine will also go through the third phase of the clinical trial, and it may take about one year to complete the clinical trial before finally reaching the conclusion on the vaccine's safety and efficacy, it said. China has approved three COVID-19 vaccine candidates for clinical trials. An adenovirus vector vaccine, developed by Institute of Military Medicine under the Academy of Military Sciences, was the first to be approved to enter a clinical trial. The first phase of the clinical trial was completed at the end of March, and the second phase started on April 12.

Meanwhile China's National Health Commission, (NHC) said on Saturday that 12 newly confirmed COVID-19 cases were reported in the country on Friday, of which 11 were imported. The other one was domestically transmitted in Heilongjiang Province bordering Russia. The death toll in the country remained at 4,632 people as no fatalities were reported due to coronavirus on Friday, it said.

The overall confirmed cases on the mainland had reached 82,816 by Friday, including 838 patients who were still being treated and 77,346 people discharged after treatment. The total number of imported cases of the coronavirus in China increased to 1,629 on Friday, of this 909 had been discharged from hospitals after recovery, and 720 were being treated with 25 in severe conditions, it said. Also on Friday, 29 asymptomatic cases were reported. So far, 983 suspected asymptomatic cases, including 150 from abroad, were still under medical observation, it said.

Coronavirus' first epicentres Hubei and its capital Wuhan had 553 asymptomatic cases under medical observation, state-run Xinhua news agency reported. The asymptomatic cases were a cause of concern as the government has lifted over two-month lockdown in Hubei and Wuhan after cases abated.

Asymptomatic cases refer to people who are tested positive for the coronavirus but develop no symptoms such as fever, cough or sore throat. They are infectious and pose a risk of spreading to others.

Catch up on all the latest Crime, National, International and Hatke news here. Also download the new mid-day Android and iOS apps to get latest updates.

Mid-Day is now on Telegram. Click here to join our channel (@middayinfomedialtd) and stay updated with the latest news

This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever

COVID-19 has brought along with it a set of side effects, from Mysophobia (the constant overdrive to wash hands and be careful of contamination) to clinical

The profession of nurse anesthesia is at crossroads in the US. While recent federal legislation and changes to the U.S. Medicare program have expanded

Home-based telerehabilitation therapy could work just as fine as traditional in-clinic therapy for stroke rehabilitation, finds a new study. The main

New study has illuminated clinical factors that are associated with the occurrence of congenital cytomegalovirus (CMV) infection in newborns. It revealed

Experience yields great results has been proved in this study. Exceptional post-operative success rates of pediatric thyroid patients, particularly children

Company: Golden Opportunities Private Limited
Experience: 4 to 8
location: Bengaluru / Bangalore
Ref: 24827452
Summary: Description Responsible for data management review to lock activities of assigned protocols and independently overseeing database update process. Answers and resolves routine data related questions....

Company: Nanu India Recruitment Co
Qualification: Bachelor Of Pharmacy (B.Pharm), MBBS, Doctor of Medicine (M.D/M.S), Master of Pharmacy (M.Pharm)
Experience: 0 to 1
Salary: 1.80 to 3.80
location: Ahmednagar, Vadodara
Ref: 24822447
Summary: Hiring For Clinical Research Pharmacovigilance....

Increasingly complex and inconsistent clinical trial regulations are causing delays, raising costs and leading to a decline in the number of international trials conducted by academics for non-commerical purposes.

None of the rats tested at Philadelphia's Wistar Institute contracted Zika after getting the vaccine. It is the best result of a Zika vaccine to date, and it is the same being tested in the first human trials.

“Even after India approves the coronavirus vaccine, it might not be possible to produce more than 10-20 million doses in the first year.”The comments came from the Chairperson of Biocon in an exclusive chat with Business Insider.Syngene, a Biocon subsidiary, is involved in accelerating a bunch of initiatives to develop a vaccine for the novel coronavirus that is spreading around the world.There are at least six vaccines under development in India, of the total 100 around the world including from the likes of Sanofi, Altimmune, and Pfizer. “Indian vaccine programmes will take some time before they get into the clinical trials, I think between 6 to 9 months depending on the programme. At least the ones we are working on, I don’t think they can get to clinics before 9 months,” Kiran Mazumdar

The actor has been involved in a clinical trial for a drug called PRO-140 since early this year. And on Tuesday, he received the news from his doctor that his virus is no longer detectable.

Tech firm Compass Pathways, has raised £64million from investors, including Peter Thiel, the Paypal co-founder. It wants to carry out research into psilocybin from magic mushrooms.

The Small Things hitmaker admits she didn't feel 'any shame' seeking help for her mental health as there is a 'history of mental health issues in her family'.

MasterChef Australia: Back To Win judge Melissa Leong has revealed she suffers from clinical depression, and has had a breakdown in the past. 

MIKE DICKSON IN NEW YORK: Roger Federer entertained Dan Evans to some private practice sessions earlier this year, and then gave him a contrastingly public schooling on Friday night.

The testing for China's fourth vaccine candidate has started today, said China National Biotec Group. It comes as CDC chief said that China could have its first coronavirus vaccine ready by autumn.

The Drug Controller of India has allowed clinical trial of Favipiravir medicine, developed indigenously a CSIR laboratory, on coronavirus patients, Director General Shekhar Mande said on Friday. He said the Indian Institute of Chemical Technology (IICT), Hyderabad has developed the technology to make the drug Favipiravir. The technology has been transferred to a private company, IICT Director S Chandrashekar said. The company will now tie up with hospitals for clinical trials so that the drug could be tested on patients suffering from COVID-19. Approval from patients will be necessary as per the protocols, he said. Mande said Favipiravir is used in countries such as China and Japan to treat influenza. Whenever, a virus enters a cell, it tries to create multiple replicas. Favipiravir stops the replication process, he explained. The CSIR has already tied up with Cadila Pharmaceuticals Ltd to evaluate Mycobacterium W (Mw) for faster recovery of hospitalised COVID-19 patients and minimise

Cham, Switzerland : Springer, [2019]

[S.l.] : SPRINGER, 2020.

New York, NY : Springer, 2019.

Cham, Switzerland : Springer, c2019.

Cham : Springer, c2019.

Cham : Springer, [2019].

Online Resource

Online Resource

Online Resource

Online Resource

Online Resource

Online Resource

Online Resource

Online Resource

Online Resource

Online Resource

Interview with Matthew H. Samore, MD, author of Clinical Decision Support and Appropriateness of Antimicrobial Prescribing: A Randomized Trial, published in the November 9 issue of JAMA, the Journal of the American Medical Association. Summary points: 1. Repetitive use of a diagnostic and treatment algorithm to ingrain new prescribing habits was a valuable part of this practice change intervention. 2. Clinical decision support systems (CDSS) are feasibly implemented in practice settings that lack electronic medical records, including rural communities. 3. CDSS needs to be integrated with tools that save clinicians' time to be sustainable.

This Viewpoint discusses considerations that might lead physicians to change their practice based on RCTs reporting non–statistically significant differences in primary outcomes, including trial methodology, totality of evidence, cost, invasiveness, and labor-intensiveness of the interventions being compared.

Jacobson, Sandra A., 1953-